Mechanisms of delayed preconditioning with A1 adenosine receptor activation in porcine coronary smooth muscle cells.
This study examined the hypothesis that the activation of A1 adenosine receptor (A1AR) induces delayed cellular protection (DCP) in porcine coronary smooth muscle cells (PCSMC). The following groups of cultured PCSMC, subjected to simulated ischemia (SI) at 20 h were studied: (a) SI: with ischemia alone; (b) A1AR agonist chloro-N6-cyclopentyl adenosine (CCPA: CCPA (1 microM) alone; (c) CCPA + PKC inhibitor chelerythrine chloride (CCL): CCPA and 1 microM CCL; (d) CCPA + iNOS inhibitor S-methylthiourea (SMT): CCPA and 100 nM SMT; (e) CCPA + KATP channel blocker Glibenclamide (Glb): CCPA and 50 microM Glb; (f) CCPA + mitochondrial KATP channel blocker 5-hydroxydecanoate (5-HD): CCPA and 100 microM of 5-HD; (g) CCPA + A1AR antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX): CCPA and 1 microM DPCPX. The release of LDH into the medium as well as the amount of LDH remaining in the cells was used as a marker of cellular injury and cell viability. Up-regulation of A1AR, epsilon-PKC, iNOS and HSP 72i was detected through Westem blot analysis. The cellular resistance (%LDH remaining in the cells) acquired by PCSMC due to CCPA (59.42 +/- 1.57) was significantly blocked by CCL: 39.30 +/- 2.03; SMT: 41.37 +/- 1.98; Glb: 47.24 +/- 1.31; 5-HD: 47.69 +/- 1.40 and DPCPX: 42.92 +/- 0.79. CCPA increased the expression of A1AR (1.30 fold), epsilon-PKC (1.20 fold), iNOS (1.50 fold), and HSP 72i (1.70 fold) compared to the controls. CCPA-induced up-regulation of A1AR, epsilon-PKC, iNOS, HSP 72i, and the opening of both mitochondrial and sarcolemmal KATP channels may possibly participate in signaling cascade. Our study suggests that A1AR activation up-regulates iNOS, HSP 72i via epsilon-PKC signaling pathway to activate both mitochondrial and sarcolemmal KATP channels for cellular protection against SI in the cultured PCSMC.
Nayeem
Mohammed A
MA
Department of Pharmacology, School of Medicine, East Carolina University, Greenville, North Carolina 27858, USA. nayeemm@mail.ecu.edu
Mustafa
S Jamal
SJ
D000241:Adenosine / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D003652:Decanoic Acids / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005905:Glyburide / Q000494:pharmacology; D050884:HSP72 Heat-Shock Proteins; D006360:Heat-Shock Proteins / Q000378:metabolism; D006880:Hydroxy Acids / Q000494:pharmacology; D019157:Ischemic Preconditioning, Myocardial; D032342:Muscle Cells / Q000187:drug effects / Q000378:metabolism; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000502:physiology*; D052247:Nitric Oxide Synthase Type II; D026902:Potassium Channel Blockers / Q000494:pharmacology; D011493:Protein Kinase C / Q000378:metabolism; D051744:Protein Kinase C-epsilon; D058906:Purinergic P1 Receptor Agonists; D058915:Purinergic P1 Receptor Antagonists; D018047:Receptors, Purinergic P1 / Q000378:metabolism; D013552:Swine; D015854:Up-Regulation
D003652:Decanoic Acids; D004791:Enzyme Inhibitors; D050884:HSP72 Heat-Shock Proteins; D006360:Heat-Shock Proteins; D006880:Hydroxy Acids; D026902:Potassium Channel Blockers; D058906:Purinergic P1 Receptor Agonists; D058915:Purinergic P1 Receptor Antagonists; D018047:Receptors, Purinergic P1; C058394:2-chloro-N(6)cyclopentyladenosine; C052853:5-hydroxydecanoic acid; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; D011493:Protein Kinase C; D051744:Protein Kinase C-epsilon; D000241:Adenosine; D005905:Glyburide